Thompson Siegel & Walmsley’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.1M | Sell |
129,881
-46,584
| -26% | -$13.2M | 0.68% | 52 |
|
|
2026
Q1 | $49.2M | Sell |
176,465
-15,496
| -8% | -$4.46M | 0.86% | 41 |
|
|
2025
Q4 | $58.2M | Sell |
191,961
-25,635
| -12% | -$8M | 0.98% | 29 |
|
|
2025
Q3 | $61M | Sell |
217,596
-88,536
| -29% | -$24.1M | 0.99% | 29 |
|
|
2025
Q2 | $73.9M | Buy |
306,132
+26,643
| +10% | +$6.3M | 1.23% | 14 |
|
|
2025
Q1 | $68.1M | Buy |
279,489
+21,336
| +8% | +$6.42M | 1.14% | 26 |
|
|
2024
Q4 | $84.8M | Sell |
258,153
-48,640
| -16% | -$16.5M | 1.32% | 13 |
|
|
2024
Q3 | $103M | Sell |
306,793
-83,227
| -21% | -$26.4M | 1.53% | 11 |
|
|
2024
Q2 | $107M | Buy |
390,020
+40,006
| +11% | +$11.6M | 1.71% | 8 |
|
|
2024
Q1 | $121M | Buy |
350,014
+1,541
| +0.4% | +$507K | 1.86% | 5 |
|
|
2023
Q4 | $113M | Buy |
348,473
+35,890
| +11% | +$11.2M | 1.82% | 4 |
|
|
2023
Q3 | $112M | Buy |
312,583
+18,419
| +6% | +$7.11M | 1.86% | 3 |
|
|
2023
Q2 | $112M | Buy |
294,164
+91,013
| +45% | +$37M | 1.78% | 5 |
|
|
2023
Q1 | $97.3M | Buy |
203,151
+1,929
| +1% | +$903K | 1.57% | 9 |
|
|
2022
Q4 | $84.6M | Buy |
201,222
+182,248
| +961% | +$73.6M | 1.37% | 12 |
|
|
2022
Q3 | $7.92M | Buy |
+18,974
| New | +$9.46M | 0.14% | 156 |
|
|
2018
Q4 | – | Sell |
-17
| Closed | -$5K | – | 749 |
|
|
2018
Q3 | $5K | Sell |
17
-17
| -50% | -$5.28K | ﹤0.01% | 716 |
|
|
2018
Q2 | $10K | Hold |
34
| – | – | ﹤0.01% | 694 |
|
|
2018
Q1 | $9K | Sell |
34
-963
| -97% | -$245K | ﹤0.01% | 692 |
|
|
2017
Q4 | $238K | Hold |
997
| – | – | ﹤0.01% | 406 |
|
|
2017
Q3 | $222K | Sell |
997
-1,875
| -65% | -$422K | ﹤0.01% | 411 |
|
|
2017
Q2 | $650K | Sell |
2,872
-2,804
| -49% | -$611K | 0.01% | 337 |
|
|
2017
Q1 | $1.13M | Sell |
5,676
-205,339
| -97% | -$39.6M | 0.01% | 346 |
|
|
2016
Q4 | $38.5M | Sell |
211,015
-60,739
| -22% | -$10.4M | 0.5% | 68 |
|
|
2016
Q3 | $44.5M | Sell |
271,754
-23,724
| -8% | -$3.6M | 0.69% | 42 |
|
|
2016
Q2 | $42.3M | Buy |
295,478
+1,987
| +0.7% | +$283K | 0.67% | 45 |
|
|
2016
Q1 | $40.1M | Buy |
293,491
+32,721
| +13% | +$4.3M | 0.65% | 47 |
|
|
2015
Q4 | $36.2M | Buy |
260,770
+19,928
| +8% | +$2.76M | 0.65% | 45 |
|
|
2015
Q3 | $32.3M | Sell |
240,842
-14,241
| -6% | -$2.05M | 0.6% | 53 |
|
|
2015
Q2 | $38.4M | Sell |
255,083
-99,666
| -28% | -$14.3M | 0.68% | 37 |
|
|
2015
Q1 | $48M | Buy |
354,749
+4,233
| +1% | +$525K | 0.83% | 24 |
|
|
2014
Q4 | $42.3M | Buy |
350,516
+15,921
| +5% | +$1.83M | 0.8% | 25 |
|
|
2014
Q3 | $37.9M | Buy |
334,595
+53,770
| +19% | +$6.37M | 0.76% | 31 |
|
|
2014
Q2 | $33.6M | Buy |
280,825
+114,991
| +69% | +$14M | 0.65% | 38 |
|
|
2014
Q1 | $21.2M | Buy |
165,834
+8,161
| +5% | +$1.05M | 0.48% | 67 |
|
|
2013
Q4 | $19.5M | Buy |
+157,673
| New | +$19.2M | 0.46% | 72 |
|
Other funds holding BIO
AI
Thompson Siegel & Walmsley's BIO Position: Q2 2026 in Review
Thompson Siegel & Walmsley reduced its Bio-Rad Laboratories Class A (BIO) stake by 26% in Q2 2026, selling an estimated $13.2M and leaving 129,881 shares worth $38.1M. The position accounts for 0.68% of the portfolio, ranked #52.
Thompson Siegel & Walmsley first reported a position in BIO in Q4 2013 and has held it in 36 quarters since. The position peaked at $121M in Q1 2024. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Thompson Siegel & Walmsley held 129,881 shares of Bio-Rad Laboratories Class A worth $38.1M as of Q2 2026.
- Thompson Siegel & Walmsley sold 46,584 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $13.2M.
- Bio-Rad Laboratories Class A made up 0.68% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #52 holding.
- Thompson Siegel & Walmsley first reported a position in Bio-Rad Laboratories Class A in Q4 2013 and has held it in 36 quarters since.
- Thompson Siegel & Walmsley's Bio-Rad Laboratories Class A position peaked at $121M in Q1 2024.
- 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.